Lasmiditan succinate (COL-144, LY573144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (Ki=2.21 nM) without vasoconstrictor activity.
Lasmiditan shows higher selectivity for the 5-HT(1F) receptor relative to other 5-HT(1) receptor subtypes than the first generation 5-HT(1F) receptor agonist LY334370[1].
Lasmiditan is orally active in two in vivo models of migraine that involve electrical stimulation of the trigeminal ganglion. After oral administration, lasmiditan potently decreases dural plasma protein extravasation and the number of c-fos positive cells in the trigeminal nucleus caudalis at a dose of 3 mg/kg[1].
[1] Nelson DL, et al. Cephalalgia. 2010, 30(10):1159-69.
















